Bio-Rad Laboratories has had a tumultuous journey lately. While the company remains steady with its
2024 revenue growth outlook, the shares have been slipping and have fallen down by
17.3%. Various financial institutions like
Truist Financial Corp and
CWM LLC have sold off their shares, which has further impacted the stock performance. At the same time,
Fisher Asset Management LLC and
Yousif Capital Management LLC have purchased shares suggesting some optimism amidst the turmoil. Notably, investors who invested three years ago are presently in the red. The company's recent earnings beat expectations, but the revenue fell short of estimates, which might have contributed to the stock decline. On the brighter side,
Bio-Rad Laboratories continues to thrive on
Global Sales and Testing Uptake, and analysts suggest looking closely at Bio-Rad considering its current stock price around
$325. However, the softness in Biopharma and stiff competition is causing setbacks. The company has maintained a pretty healthy balance sheet, still, not all investors are convinced by its revenues suggesting a mixed perspective in the market. Bio-Rad Laboratories is recently reported to onboard new executive vice president and CFO,
Roop Lakkaraju.
Bio-Rad Laboratories Stocks News Analytics from Tue, 20 Jul 2021 07:00:00 GMT to Tue, 07 May 2024 22:27:43 GMT -
Rating -3
- Innovation 2
- Information 5
- Rumor -4
